Safety and immunogenicity of a new trivalent inactivated split-virus influenza
vaccine in healthy Korean children: a randomized, double-blinded,
active-controlled, phase III study.
Author(s): Kang JH, Oh CE, Lee J, Lee SY, Cha SH, Kim DS, Kim HH, Lee JH, Kim JT, Ma SH,
Hong YJ, Cheong HJ, Lee HJ.
Affiliation(s): Department of Pediatrics, Seoul St. Mary's Hospital, The Catholic University of
Korea, Seoul, Korea.
Publication date & source: 2011, J Korean Med Sci. , 26(11):1421-7
We report results of a randomized, double-blinded, active-controlled, phase III
study conducted to evaluate the immunogenicity and safety of a new trivalent
inactivated split-virus influenza vaccine (GC501) manufactured by the Green Cross
Corporation in Korea. A total of 283 healthy children aged 6 months to < 18 yr
were randomized to receive either GC501 or control. Of the GC501 recipients,
seroconversion occurred in 48.5% for A/H1N1, 67.7% for A/H3N2 and 52% for
influenza B. The proportion of subjects who had post-vaccination
hemagglutination-inhibition titers of 1:40 or greater was 90.7% for A/H1N1, 86.8%
for A/H3N2 and 82.4% for influenza B in the GC501 recipients. No serious adverse
events related to vaccination, or withdrawals because of adverse events were
reported. The majority of solicited adverse events were mild in intensity. GC501
vaccine has good tolerability and favorable immunogenicity in children aged 6
months to < 18 yr. The addition of one more brand of influenza vaccine may allow
for better global accessibility of vaccine for epidemics or future pandemics.
|